Ezogabine in ALS

Study Description: This research is being done in order to understand more about motor neurons in people who have amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) compared to people without ALS. Past research has shown that the motor neurons of ALS patients may be producin more electrical activity than motor neurons of people without ALS, and that this extra electrical activity tires the neurons and contributes to their death.

Contact for Enrollment

     (706) 721-2681

    Submit Information Online

Principal Investigator: Michael Rivner

Eligibility Criteria: ALS Volunteers: Subjects may be eligible for this study if they: Are male or female, between the ages of 18 to 80. Have been diagnosed with ALS. Have a Slow vital capacity (SVC) measure of ? 50% of predicted for gender, height and age at the Screening Visit. Are able to swallow oral medication at the Screening Visit and expected to be able to swallow tablets throughout the course of the study. Subjects may not be elegible for this study if they: Have serum AST or ALT value > 2.0 times the upper normal limit. ( Test for liver damage) Have significant conduction abnormalities on an ECG, a known history of heart problems or of heart attacks within the past 24 months, or have congestive heart failure. Are on a digoxin treatment. Have a history of urinary retention or use medication to treat urinary retention. Matched and Unmatched Healthy Controls: Subjects may be elegible for this study if they: Are a male or female, aged 18 to 80 Are capable of providing informed consent and following trial procedures. Are on a fixed dose of medications known to affect the neurophysiology measures in the study for 30 days before the Screening Visit. Use of these medications can not be on an as needed basis and there must be no reason to believe that a change in dose would be necessary during the course of the study. Subjects may not be elegible for this study if: Have a history of ALS or other neurodegenerative disease. Have a presence of a neurological disorder. Have a presence of positive family history of ALS.

Compensation: Yes, subjects will be compensated.

Compensation Explanation: ALS Volunteers will be paid $200.00 at the end of the study using clincard. Matched and unmatched healthy volunteers will be paid $100.00 at the end of the study using clincard. they will provide a w-9 prior to payment


Didn't find a study to participate in?

If you don't see specific studies that interest you, please submit your contact information for future studies.